Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. (PCSA) on July 17, 2024, covering events occurring on July 15 and July 16, 2024. The filing primarily addresses significant changes in executive leadership, specifically the departure of the former Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure of CFO: James Stanker resigned as Chief Financial Officer effective July 15, 2024, by mutual agreement. He will remain a part-time employee to facilitate a smooth transition.
- Appointment of New CFO: Russell Skibsted was appointed Chief Financial Officer effective July 16, 2024. Mr. Skibsted brings nearly 30 years of pharmaceutical industry experience, including previous CFO roles at Alimera Sciences, Rockwell Medical, and BioTime (now Lineage Cell Therapeutics).
Compensation and Outlook
Mr. Skibsted's employment agreement includes the following compensation terms:
- Base Salary: $400,000 annually, with eligibility for a $50,000 increase upon achieving specified goals.
- Bonus: Target bonus of 35% of base compensation.
- Equity: Award of 28,000 restricted stock units (RSUs) effective July 16, 2024, vesting upon achievement of certain goals.
The filing includes a Safe Harbor Statement noting that forward-looking statements regarding Mr. Skibsted's service and start date are subject to risks and uncertainties detailed in the Company's Form 10-K and Form 10-Q filings.
Investor Verification Checklist
- Verify the transition timeline and the extent of Mr. Stanker's part-time involvement.
- Review the specific performance goals tied to Mr. Skibsted's salary increase and RSU vesting in the attached Employment Agreement (Exhibit 10.1).
- Confirm the impact of this leadership change on the Company's capital raise and investor relations strategies, given Mr. Skibsted's background.
- Check subsequent filings for any updates to the Company's liquidity position or operational plans following the leadership transition.